Lupin gets USFDA nod to market fungal infection cream

Image
Press Trust of India New Delhi
Last Updated : Jun 04 2018 | 5:45 PM IST

Drug firm Lupin today said it has received final approval from the US health regulator to market its Nystatin and Triamcinolone Acetonide cream used for treatment of a type of fungal infection.

The company's product is is the generic version of Delcor's Mycolog-II cream. It is indicated for the treatment of cutaneous candidiasis, Lupin said in a filing to the BSE.

"The company has received final approval for its Nystatin and Triamcinolone Acetonide cream USP, 100,000 units/gram and 1mg/gram, from the United States Food and Drug Administration (USFDA)...," it added.

As per IQVIA MAT April 2018 data, Nystatin and Triamcinolone Acetonide Cream USP, 100,000 units/gram and 1mg/gram, had annual sales of around USD 62.2 million in the US market.

Shares of Lupin Ltd today closed at Rs 772.40 per scrip on BSE, up 1.22 per cent from the previous close.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jun 04 2018 | 5:45 PM IST

Next Story